Cargando…

The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid

Background: Acetylsalicylic acid (ASA) is part of the recommended treatment of Kawasaki disease (KD). Controversies remain regarding the optimal dose of ASA. We aimed to evaluate the impact of different doses of ASA on inflammation control while minimizing adverse effects in the acute phase treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Jung Eun, Roh, Da Eun, Kim, Yeo Hyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602855/
https://www.ncbi.nlm.nih.gov/pubmed/33081227
http://dx.doi.org/10.3390/children7100185
_version_ 1783603781780373504
author Kwon, Jung Eun
Roh, Da Eun
Kim, Yeo Hyang
author_facet Kwon, Jung Eun
Roh, Da Eun
Kim, Yeo Hyang
author_sort Kwon, Jung Eun
collection PubMed
description Background: Acetylsalicylic acid (ASA) is part of the recommended treatment of Kawasaki disease (KD). Controversies remain regarding the optimal dose of ASA. We aimed to evaluate the impact of different doses of ASA on inflammation control while minimizing adverse effects in the acute phase treatment of KD. Methods: The enrolled 323 patients with KD were divided into three groups according to ASA dose: moderate-dose (30–50 mg/kg/day), high-dose (80–100 mg/kg/day), and non-ASA. Results: High-dose ASA group showed a significantly shorter duration of fever from the start of treatment to remission than other groups. Baseline level and delta score of interleukin (IL)-1, IL-6, IL-10, tumor necrosis factor-α, and transforming growth factor β were not statistically different among the groups. The number of patients who received additional treatments in the non-ASA group was more than other groups. Coronary artery dilatation was not significantly different among the groups. One patient with high-dose ASA was diagnosed with Reye syndrome. Conclusion: Different doses of ASA did not show any differences in changes of inflammatory bio-makers and cytokines. However, high-dose ASA showed occurrence of Reye syndrome, and non-ASA showed intravenous immunoglobulin refractoriness. We suggest that moderate-dose ASA may be beneficial for the treatment of patients in the acute phase of KD.
format Online
Article
Text
id pubmed-7602855
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76028552020-11-01 The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid Kwon, Jung Eun Roh, Da Eun Kim, Yeo Hyang Children (Basel) Article Background: Acetylsalicylic acid (ASA) is part of the recommended treatment of Kawasaki disease (KD). Controversies remain regarding the optimal dose of ASA. We aimed to evaluate the impact of different doses of ASA on inflammation control while minimizing adverse effects in the acute phase treatment of KD. Methods: The enrolled 323 patients with KD were divided into three groups according to ASA dose: moderate-dose (30–50 mg/kg/day), high-dose (80–100 mg/kg/day), and non-ASA. Results: High-dose ASA group showed a significantly shorter duration of fever from the start of treatment to remission than other groups. Baseline level and delta score of interleukin (IL)-1, IL-6, IL-10, tumor necrosis factor-α, and transforming growth factor β were not statistically different among the groups. The number of patients who received additional treatments in the non-ASA group was more than other groups. Coronary artery dilatation was not significantly different among the groups. One patient with high-dose ASA was diagnosed with Reye syndrome. Conclusion: Different doses of ASA did not show any differences in changes of inflammatory bio-makers and cytokines. However, high-dose ASA showed occurrence of Reye syndrome, and non-ASA showed intravenous immunoglobulin refractoriness. We suggest that moderate-dose ASA may be beneficial for the treatment of patients in the acute phase of KD. MDPI 2020-10-16 /pmc/articles/PMC7602855/ /pubmed/33081227 http://dx.doi.org/10.3390/children7100185 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kwon, Jung Eun
Roh, Da Eun
Kim, Yeo Hyang
The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid
title The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid
title_full The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid
title_fullStr The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid
title_full_unstemmed The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid
title_short The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid
title_sort impact of moderate-dose acetylsalicylic acid in the reduction of inflammatory cytokine and prevention of complication in acute phase of kawasaki disease: the benefit of moderate-dose acetylsalicylic acid
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602855/
https://www.ncbi.nlm.nih.gov/pubmed/33081227
http://dx.doi.org/10.3390/children7100185
work_keys_str_mv AT kwonjungeun theimpactofmoderatedoseacetylsalicylicacidinthereductionofinflammatorycytokineandpreventionofcomplicationinacutephaseofkawasakidiseasethebenefitofmoderatedoseacetylsalicylicacid
AT rohdaeun theimpactofmoderatedoseacetylsalicylicacidinthereductionofinflammatorycytokineandpreventionofcomplicationinacutephaseofkawasakidiseasethebenefitofmoderatedoseacetylsalicylicacid
AT kimyeohyang theimpactofmoderatedoseacetylsalicylicacidinthereductionofinflammatorycytokineandpreventionofcomplicationinacutephaseofkawasakidiseasethebenefitofmoderatedoseacetylsalicylicacid
AT kwonjungeun impactofmoderatedoseacetylsalicylicacidinthereductionofinflammatorycytokineandpreventionofcomplicationinacutephaseofkawasakidiseasethebenefitofmoderatedoseacetylsalicylicacid
AT rohdaeun impactofmoderatedoseacetylsalicylicacidinthereductionofinflammatorycytokineandpreventionofcomplicationinacutephaseofkawasakidiseasethebenefitofmoderatedoseacetylsalicylicacid
AT kimyeohyang impactofmoderatedoseacetylsalicylicacidinthereductionofinflammatorycytokineandpreventionofcomplicationinacutephaseofkawasakidiseasethebenefitofmoderatedoseacetylsalicylicacid